{"organizations": [], "uuid": "dbfbc7872da3b21a145a4125ed16782b0893e29c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-vistagen-therapeutics-receives-fda/brief-vistagen-therapeutics-receives-fda-fast-track-designation-for-av-101-for-treatment-of-major-depressive-disorder-idUSASB0BZKX", "country": "US", "domain_rank": 408, "title": "BRIEF-Vistagen Therapeutics Receives FDA Fast Track Designation For Av-101 For Treatment Of Major Depressive Disorder", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-03T15:37:00.000+02:00", "replies_count": 0, "uuid": "dbfbc7872da3b21a145a4125ed16782b0893e29c"}, "author": "", "url": "https://www.reuters.com/article/brief-vistagen-therapeutics-receives-fda/brief-vistagen-therapeutics-receives-fda-fast-track-designation-for-av-101-for-treatment-of-major-depressive-disorder-idUSASB0BZKX", "ord_in_thread": 0, "title": "BRIEF-Vistagen Therapeutics Receives FDA Fast Track Designation For Av-101 For Treatment Of Major Depressive Disorder", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "treatment of major depressive disorder reuters staff", "sentiment": "none"}, {"name": "vistagen therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 3, 2018 / 1:37 PM / in 4 minutes BRIEF-Vistagen Therapeutics Receives FDA Fast Track Designation For Av-101 For Treatment Of Major Depressive Disorder Reuters Staff 1 Min Read \nJan 3 (Reuters) - Vistagen Therapeutics Inc: \n* VISTAGEN THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR AV-101 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER \n* VISTAGEN THERAPEUTICS INC - ‍ON TRACK TO DOSE FIRST PATIENT IN AV-101 PHASE 2 MDD ADJUNCTIVE TREATMENT STUDY IN Q1 OF 2018​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-03T15:37:00.000+02:00", "crawled": "2018-01-03T15:53:23.008+02:00", "highlightTitle": ""}